PUMA BIOTECHNOLOGY, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.95 USD | -3.60% |
|
+3.81% | +13.88% |
| May. 02 | Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
| May. 02 | Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024 | CI |
Evolution of the average Target Price on Puma Biotechnology, Inc.
Price target over the last 5 years
History of analyst recommendation changes
b9b7b480f0.qf-jeKZSWmgn_2c9b6GVwPL62YkIfxZEL9EWElx33ac.w5bsIe8YNFAKhQhFGO_Gl4Szr9FGJm8yH4FDajU9gsn4stIrlRxuP2GvJg~ab0f1d5ef31718b6271098830634f8f6
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
5.135
USD
Average target price
4.333
USD
Spread / Average Target
-15.61%
High Price Target
7
USD
Spread / Highest target
+36.32%
Low Price Target
2
USD
Spread / Lowest Target
-61.05%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Puma Biotechnology, Inc.
| HC Wainwright | |
| Citigroup | |
| RBC Capital Markets |
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
- Stock Market
- Equities
- PBYI Stock
- Consensus Puma Biotechnology, Inc.
